MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

JCR and MEDIPAL announced that the first participant has been dosed in a global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB. The milestone advances clinical development of a potential treatment for the rare genetic disorder, though no efficacy or safety data were disclosed.